Expert insights. Personalized for you.
NORML
MAY 26, 2020
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Adverse events were mostly mild and resolved spontaneously.
Cannabis Life Network
NOVEMBER 18, 2020
announced early this morning that it will undertake a clinical trial of psilocybin-assisted psychotherapy. About the Research & Clinical Trial Numinus Wellness […]. Vancouver based Numinus Wellness Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 21, 2021
The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The Principal Investigator for the trial will be Kevin Boehnke, Ph.D.,
Cannabis Law Report
AUGUST 10, 2021
Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc.
Cannabis Law Report
AUGUST 24, 2021
Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19.
Cannabis Law Report
JUNE 16, 2021
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin.
Veriheal
MAY 3, 2022
The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size.
Cannabis Law Report
JUNE 1, 2021
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain.
Cannabis Law Report
FEBRUARY 10, 2022
Radicle Science launches several blinded placebo-controlled clinical trials on rare cannabinoids with 10,000 participants in the first half of 2022 on the heels of completing 25 large-scale CBD studies in 2021.
Cannabis Law Report
DECEMBER 14, 2021
IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. POTOMAC, Md.–(BUSINESS
Cannabis Law Report
APRIL 1, 2022
We are pleased to announce the successful dosing of more than half of the subjects in Part A of our ongoing Phase 2 clinical trial, a study designed to evaluate the safety and effectiveness of ANEB-001 in treating ACI,” said Simon Allen, Chief Executive Officer of Anebulo.
|
Cannabis Law Report
APRIL 5, 2022
Efficacy data from fully funded Phase 2 trial is expected in first half of 2022. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control tumor necrosis factor-alpha (TNF-?),
Cannabis Law Report
DECEMBER 9, 2021
The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.
Puff Puff Post
MARCH 10, 2020
“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs.
Cannabis Law Report
FEBRUARY 23, 2022
Efficacy data from fully funded Phase 2 trial is expected in first half of 2022. The primary endpoint for the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of (TNF-?),
Cannabis Law Report
SEPTEMBER 13, 2021
Key objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF-?, The primary goal of this Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the levels of tumor necrosis factor-alpha (TNF-?)
Cannabis Law Report
DECEMBER 20, 2021
Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., First Patient Expected to be Enrolled by Q2 of 2022.
Puff Puff Post
NOVEMBER 5, 2019
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. ” “This is a significant milestone for the Company as we transition from a preclinical to a clinical stage organization,” says Eric A.
Puff Puff Post
MARCH 10, 2020
VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).
Puff Puff Post
NOVEMBER 5, 2019
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. ” “This is a significant milestone for the Company as we transition from a preclinical to a clinical stage organization,” says Eric A.
Cannabis Law Report
JANUARY 7, 2020
With our recent event in Cape Town, we have now brought CannaTech to every continent and helped build the cannabis footprint across the world. The first PsyTech Summit Global Event will take place in Tel Aviv on March 29-30, 2020. Here’s the press release we received this morning.
TheAnswerPage
NOVEMBER 29, 2021
What serious adverse events have been noted in psilocybin clinical trials?
TheAnswerPage
MARCH 11, 2022
In the clinical trials evaluating a purified CBD product (Epidiolex) in epilepsy patients, side effects including sedation, decreased appetite, diarrhea, sleep disturbance, infections, pneumonia, viral infections and weight loss were reported.
The Joint Blog
APRIL 17, 2020
According to a new study in the Journal of Clinic Medicine , the use of Tetrahydrocannabinol (THC) could have adverse drug effects when combined with other medications due to drug-drug interactions.
TheAnswerPage
FEBRUARY 23, 2022
Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). Some of these studies have shown positive results, but adverse events were also noted.
Cannabis Law Report
MAY 10, 2022
Combined with our existing cash on hand, we are sufficiently capitalized for operations through 2025, inclusive of budget allocations for planned clinical trials and without having to look to the capital markets for any additional funds. Nets CAD$15,480,780 cash in non-dilutive capital.
Cannabis Law Report
MAY 23, 2022
In addition, it is expected that the original patent-pending formulation, Masaya Pure , will be used in Flora’s current clinical trials with the University of Manchester in the UK. FORT LAUDERDALE, Fla. & & TORONTO–(BUSINESS WIRE)–Flora Growth Corp.
Cannabis Law Report
JANUARY 27, 2022
The majority of industry-sponsored drugs in active clinical development for FXS are in Phase II, with two drugs in Phase III. The US has a substantial lead in the number of FXS clinical trials globally. Clinical trial activity in the FXS space is dominated by completed trials.
Cannabis Law Report
DECEMBER 15, 2021
A number of clinical trials have been investigating the potential of psychedelics in mental health treatment. The psychedelic drug trial for terminally ill patients that’s brought researchers to tears. The ABC (Australia) reports.
Cannabis Law Report
AUGUST 17, 2021
Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Primary endpoint showed a median 16.6%
Cannabis Law Report
FEBRUARY 25, 2022
Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. TORONTO–(BUSINESS WIRE)– $HUGE #FSDPharma –FSD Pharma Inc.
Cannabis Law Report
MAY 24, 2022
Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), today announced the appointment of Dr. Kenneth Cundy, Ph.D.
Cannabis Law Report
NOVEMBER 19, 2021
“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”
Cannabis Law Report
JULY 28, 2021
The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. Subject to the approval of Health Canada, the licence will effectively enable KGK to offer a turn-key solution for third parties to conduct clinical trials involving psychedelic molecules, while also authorizing KGK to act as a centralized distributor for large, multi-location clinical trials.
Cannabis Law Report
OCTOBER 28, 2021
Psymposia report… O n Sep 23, 2021, Psymposia staff received an email from the personal email account of Mark Haden — the former Executive Director of psychedelic nonprofit MAPS Canada and current Director of Clinical Trials for Psygen Inc.
Cannabis Law Report
SEPTEMBER 9, 2021
Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. Investors may register for the conference at the event website. The live and archived webcast will be available for 90 days after the event.
Cannabis Law Report
AUGUST 3, 2021
Actual results and future events could differ materially from those anticipated in such information. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products.
266 
Let's personalize your content